I-Mab Announces Poster Presentations of CD47 Antibody Lemzoparlimab and CD73 Antibody Uliledlimab at SITC 2022
Details of the poster presentations are as follows:
Title: |
Combination of Lemzoparlimab and HER2 ADC Elicits Enhanced Activity against HER2 Expressing Tumors |
Abstract ID: |
859 |
Presenter: |
Dr. |
Date/Time: |
|
Title: |
Revealing Novel Immune Modulatory Mechanism of Uliledlimab through the Blockade of CD73 Pathway |
Abstract ID: |
1151 |
Presenter: |
Dr. |
Date/Time: |
|
Full text of the abstracts will be released on the SITC website at
About CD47 and Lemzoparlimab
CD47 is a cell surface protein over-expressed in a wide variety of cancers and can act to protect tumors by delivering a "don't eat me" signal to otherwise tumor-engulfing macrophages. CD47 antibody blocks this signal and enables macrophages to attack tumor cells. However, development of CD47 antibody as a cancer therapy has been hampered by its hematologic side effects, such as severe anemia, caused by natural binding of CD47 antibody to red blood cells. Scientists at
Multiple clinical studies of lemzoparlimab are ongoing to explore indications in treating patients with myelodysplastic syndrome (MDS), acute myelocytic leukemia (AML), non-Hodgkin's lymphoma (NHL), and advanced solid tumors in combination with chemotherapy and immune checkpoint inhibitors.
About Uliledlimab
Uliledlimab (also known as TJD5) is a differentiated, humanized antibody against CD73, an ecto-enzyme expressed on stromal cells and tumors that converts extracellular adenosine monophosphate (AMP) to adenosine. Adenosine in turn binds to adenosine receptors on relevant immune cells and inhibits anti-tumor immune responses in tumor microenvironment. Uliledlimab is expected to offer clinical benefit by suppressing tumor growth in concert with checkpoint therapies such as PD-(L)1 antibodies. Uliledlimab is effective in anti-tumor activities through a unique intra-dimer binding, leading to differentiated and favorable functional properties as evident in preclinical studies.
About
I-Mab Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding data from preclinical studies of lemzoparlimab or uliledlimab, the potential implications of clinical data for patients, and
I-Mab Contacts
Chief Operating Officer, Interim Chief Financial Officer
|
Chief Communications Officer
|
Investor Inquiries
E-mail: emilie@thepiacentegroup.com Office line: +86 21 6039 8363 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/i-mab-announces-poster-presentations-of-cd47-antibody-lemzoparlimab-and-cd73-antibody-uliledlimab-at-sitc-2022-301641244.html
SOURCE